Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

1. The number and function of circulating endothelial progenitor cells (EPCs) are inversely associated with coronary risk factors and atherosclerotic diseases such as coronary artery disease (CAD) and cardiovascular high risk.

2. This double-blind, randomized, placebo-controlled trial to evaluate the effects of cilostazol on human early EPCs and endothelial function as well as the potential mechanisms of action in patients with CAD and cardiovascular high risk.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cheng-Kung University Hospital
• Collaborator: Department of Health, Executive Yuan, R.O.C. (Taiwan)
• Treatments: Cilostazol

Criteria

Inclusion Criteria:

• stable CAD documented by stress test, computed tomography angiography or coronary angiography or

• old myocardial infarction (>6 months)

• history and evidence of CAD

• history and evidence of cerebrovascular accident

• history and evidence of peripheral artery disease

• diabetes mellitus

• metabolic syndrome

• stage 3 to 5 chronic kidney disease

• at least 2 of the followings: male ≥45 years old or female ≥55 years old; hypertension; current or past 3-year tobacco smoking; hyperlipidemia; family history of premature CAD (male <55 years old or female <65 years old)

Exclusion Criteria:

• unstable CAD

• have plan to do percutaneous intervention or bypass surgery for CAD or peripheral artery disease within recent 3 months

• severe liver dysfunction (transaminases >10 times of upper normal limit, history of liver cirrhosis, or hepatoma)

• left ventricular ejection fraction (<50% by echocardiography)

• documented active malignancy

• chronic inflammatory disease

• known drug allergy history for cilostazol

• current use of cilostazol or any other cAMP-elevator

• premenopausal women